BCLI · Brainstorm Cell Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $4.17M | $4.65M | $10.75M | $13.96M | $15.23M | $22.33M |
| SG&A | $5.78M | $7.04M | $10.69M | $10.87M | $9.30M | $9.36M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $199.0K | $240.0K | $265.0K | $285.0K | $260.0K | $219.0K |
| Operating Income | ($9.95M) | ($11.69M) | ($21.44M) | ($24.82M) | ($24.54M) | ($31.68M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($10.31M) | ($11.62M) | ($17.19M) | ($24.28M) | ($24.46M) | ($31.81M) |
| EPS - Basic | ($1.11) | ($2.31) | ($6.00) | ($9.90) | ($16.05) | - |
| EPS - Diluted | ($1.11) | ($2.31) | ($6.00) | ($9.90) | ($16.05) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.0K | $187.0K | $1.30M | $772.0K | $18.86M | $37.83M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $7.07M | $6.08M | $4.95M | $6.22M | $3.70M | $5.42M |
| Current Assets | $307.0K | $385.0K | $1.90M | $3.11M | $23.28M | $43.24M |
| Total Assets | $1.02M | $1.83M | $4.21M | $8.45M | $29.28M | $51.26M |
| Current Liabilities | $11.01M | $8.98M | $7.80M | $8.80M | $6.32M | $11.23M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $11.01M | $9.60M | $9.07M | $11.47M | $9.94M | $15.79M |
| Stockholders' Equity | ($9.98M) | ($7.76M) | ($4.86M) | ($3.02M) | $19.34M | $35.46M |
| Retained Earnings | ($236.94M) | ($226.64M) | ($215.01M) | ($197.82M) | ($173.54M) | ($149.09M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.97M) | ($9.09M) | ($20.46M) | ($19.32M) | ($26.27M) | ($35.19M) |
| Investing Cash Flow | - | $12.0K | $2.19M | $998.0K | $323.0K | ($4.45M) |
| Financing Cash Flow | $6.88M | $7.97M | $18.98M | $238.0K | $6.97M | $76.94M |
| CapEx | - | - | $18.0K | $29.0K | $330.0K | $378.0K |
| Free Cash Flow | - | - | ($20.48M) | ($19.35M) | ($26.59M) | ($35.57M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.19 | 0.80 | 1.09 | 1.12 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -1008.5% | -634.4% | -408.6% | -287.3% | -83.5% | -62.1% |
| Return on equity | 103.2% | 149.7% | 353.9% | 805.2% | -126.4% | -89.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 |
| Quick ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 |
| Cash ratio | 0.00 | 0.02 | 0.17 | 0.09 | 2.98 | 3.37 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -0.10 | -0.24 | -0.87 | -2.80 | 1.51 | 1.45 |
| Liabilities / Assets | 10.77 | 5.24 | 2.15 | 1.36 | 0.34 | 0.31 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | 92.6x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 14.9% | 45.5% | 13.6% | -1.2% | 22.6% | -37.8% |
| Net income growth (YoY) | 11.3% | 32.4% | 29.2% | 0.7% | 23.1% | -36.8% |
| EPS growth (YoY) | 51.9% | 61.5% | 39.4% | 38.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -5.8% | 27.2% | 25.2% | -203.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -28.6% | -59.8% | -61.1% | - | -45.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BRAINSTORM CELL THERAPEUTICS INC. against the 5 most active filers in the same SIC group.